Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

mirxes
TO KNOW. TO ACT.

Mirxes Holding Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2629)

VOLUNTARY ANNOUNCEMENT
FORMATION OF JOINT VENTURE

This announcement is made by Mirxes Holding Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

FORMATION OF JOINT VENTURE

The board (the "**Board**") of directors (the "**Director(s)**") of the Company announces that on October 6, 2025, Mirxes International Holding Limited, a wholly-owned subsidiary of the Company, entered into a joint venture agreement with Xeraya Opportunities Fund PCC Limited ("**Xeraya**") to establish MYRNA DIAGNOSTICS SDN. BHD., a joint venture company (the "**Joint Venture**"). The Joint Venture is held as to 40% by Mirxes International Holding Limited and 60% by Xeraya. The Company and Xeraya have agreed to contribute approximately US$2 million and US$3 million in cash in proportion to their respective equity interests to the registered capital of the Joint Venture, respectively. The purpose of the Joint Venture shall be to conduct research, development, commercialization, and obtain regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia.

INFORMATION OF XERAYA

Xeraya, the brainchild of Khazanah Nasional Berhad, is a life sciences-focused investment firm that invests to enable the development of breakthrough solutions to address unmet needs in healthcare and sustainability through long-term, partnership-driven venture capital and private equity investments. To the best of the directors' knowledge, information and belief, Xeraya is a shareholder of the Company and does not constitute a substantial shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company.

REASONS FOR AND BENEFITS OF FORMATION OF JOINT VENTURE

Malaysia, a dynamic upper-middle-income economy with a population of over 35 million people, is facing an escalating cancer burden, with approximately 51,650 new cancer cases and 31,633 deaths recorded in 2022 (Global Cancer Observatory, 2022). Notably, over 60% of cancers in Malaysia are diagnosed at late stages (Stage III or IV), severely limiting survival outcomes and placing strain on the national healthcare system (National Strategic Plan for Cancer Control Programme, 2021–2025). With Malaysia's cancer incidence estimated to increase by more than 70% by 2050 (Global Cancer Observatory, 2022), early detection remains an urgent critical unmet need, especially for high-incidence cancers such as lung, colorectal, breast, liver and gastric cancers, which collectively account for nearly 50% of all cases.

Through the strategic joint venture with Xeraya, with its strong regional life-sciences and healthcare expertise, deep operational roots and extensive network in Malaysia, the Company intends to:

(i) build Malaysia's leading cancer omics platform, anchored on the Company's state-of-the-art miRNA centric multi-omic technology platform and proven blood-based cancer early detection tests, to address Malaysia's critical clinical unmet needs in cancer early detection and precision medicine;

(ii) establish a strong and localized specialty omics testing operation in Malaysia,

   a. to scale existing clinical business through localized testing services, which improves turnaround time and cost-efficiency for existing customers;

   b. to fast-track engagement and entry into new market segment including public healthcare institutions;

(iii) leverage Malaysia's robust biotechnology and healthcare ecosystem to fast-track development and clinical pipeline including colorectal, breast, liver and multi-cancers;

(iv) synergize R&D and clinical operations in Singapore, China and Malaysia, to accelerate regulatory approval of in vitro diagnostics (IVDs) and deployment of innovative lab-developed tests (LDTs); and

(v) establish a scalable regional platform, using Malaysia as a launchpad for future expansion into neighboring ASEAN and other Asian markets with similar epidemiological profiles, ethnic and genetic backgrounds and unmet screening needs.

The Board believes that entering into the Joint Venture represents a strategic and synergistic move aligned with the Company's mission — to make diagnostic solutions for early detection of diseases accessible on a global scale, beginning with addressing one of the most pressing healthcare gaps in Malaysia and the region.

LISTING RULES IMPLICATIONS

As the highest of the applicable percentage ratios (as defined under the Listing Rules) is less than 5%, the formation of the Joint Venture does not constitute a notifiable transaction for the Company under Chapter 14 of the Listing Rules. As Xeraya is not a connected person of the Company, the formation of the Joint Venture also does not constitute a connected transaction for the Company under Chapter 14A of the Listing Rules. This announcement is made on a voluntary basis.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, October 6, 2025

As at the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan, Dr. ZOU Ruiyang and Mr. HO Hou Chiat, Isaac as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Dr. LAM Sin Lai Judy, Mr. FANG Xiao and Ms. MA Andrea Lo Ling as independent non-executive Directors.